Europe gives green light to AbbVie hepatitis C medicine, others

LONDON, Nov 21 (Reuters) - European regulators recommended approval for AbbVie's hepatitis C drug dasabuvir, an experimental all-oral regimen for patients infected with the virus that could be an alternative to long courses of a combination of pills and injections.